Femke M.A.P. Claessen - Orthopaedic Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Ilse Schol - Orthopaedic Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Gregory P. Kolovich - Orthopaedic Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
David Ring - The University of Texas at Austin, Austin, TX, USA

No consensus regarding optimal treatment or etiology of Preiser disease exists. We described the epidemiology,classification and treatment characteristics of 18 patients with Preiser disease. Patients with changes related to previoustrauma, and without radiographs were excluded. Based on the radiographs at diagnosis, we classified 13 scaphoids asHerbert Lanzetta stage II, four as stage III, and one as stage IV. In 12 patients nonspecific treatment was offered andonly two patients received surgical treatment. We found that chosen treatment is not associated with the severity ofHerbert Lanzetta stage and the outcome is not influenced by chosen treatment.Level of evidence: I

Avascular necrosis, osteonecrosis scaphoid, preiser disease, retrospective study, Treatment